arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Orchestra BioMed Holdings, Inc.

OBIO

$4.22 ▲ +0.06 (+1.44%) at close

6 Visible periods

28 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Orchestra BioMed Holdings, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $201.5M

Dividend Yield —

Revenue Growth 1169.2% ↗

Op. Margin -154.7%

ROIC -272.9% ↗

FCF / Share $-1.04 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$33.48M

↑ +1169.2% —

Net Income Profit after all expenses

$-52.70M

↑ +13.6% —

FCF / Share Free cash flow per share

$-1.04

↑ +25.0% —

Long-Term Debt Long-term obligations

$15.00M

— 0.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Revenue Growth YoY (%)	1169.2% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+14515%)	-4.4% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-155%)	-21.9% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-373%)	—	—	—
EPS Growth YoY (%)	33.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-12.2% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	33.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-11100.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	13.6% Fair ↑ Fair Improving Year-over-year change in net income	-24.2% Weak ↑ Weak Improving Year-over-year change in net income	-46.2% Weak Weak Year-over-year change in net income	-8773.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	25.0% Good ↑ Good Improving Year-over-year change in free cash flow	0.7% Caution ↑ Caution Improving Year-over-year change in free cash flow	30.2% Excellent Excellent Year-over-year change in free cash flow	-14868.1% Weak Weak Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	111.6% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Operating Margin (%) (%)	-154.7% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1132%)	—	—	—	—	—
Profit Margin (%) (%)	-157.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1412%)	—	—	—	—	—
FCF Margin (%) (%)	-147.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—
FCF / Net Income (x)	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Return on Invested Capital (%)	-272.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-338.7% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	7.9% Fair Fair Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-45.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-84.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-54.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-34.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-0.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	—	—	—	—	9.6% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-36%)	—

⚖️ Is the balance sheet risky? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Interest Coverage (x)	—	-216.50x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-36.79x Weak Weak Operating income divided by interest expense Optimal: > 5x	-25.12x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-19.69M	$-7.26M	$-30.56M	$-19.78M	$-1.75M	$-2.03M
Debt / EBITDA (x)	-0.29x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.23x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Revenue per Share (USD)	$0.70	$0.07	$0.08	$0.24	—	—
Basic EPS, GAAP (USD)	$-1.11	$-1.66	$-1.48	$-2.24	$-0.02	—
Free Cash Flow per Share (USD)	$-1.04	$-1.38	$-1.39	$-1.99	$-0.01	—
Book Value per Share (USD)	—	—	—	—	$-0.89	$-0.80
Tangible Book Value per Share (USD)	—	—	—	—	$-0.89	$-0.80
Basic Weighted Avg Shares (shares)	47.75M	36.82M	33.23M	14.99M	20.45M	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Working Capital (USD)	$91.17M	$52.96M	$77.91M	$66.12M	$1.64M	$2.03M
LT Debt (USD)	$15.00M	$15.00M	—	—	—	—
Total Equity (USD)	—	—	—	—	$-3.94M	$-3.56M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Sales/Revenue/Turnover (USD)	$33.48M	$2.64M	$2.76M	$3.53M	—	—
Depreciation Expense (USD)	$327.00K	$308.00K	$287.00K	$222.00K	—	—
Net Income, GAAP (USD)	$-52.70M	$-61.02M	$-49.12M	$-33.61M	$-378.75K	—
Operating Cash Flow (USD)	$-48.96M	$-50.56M	$-46.13M	$-29.29M	$-272.36K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 24 quarters

Orchestra BioMed Holdings, Inc.

Analytical Summary

6-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare OBIO with peers